Endologix (ELGX) : Traders are bullish on Endologix (ELGX) as it has outperformed the S&P 500 by a wide margin of 12.55% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 4.24%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 4.8% in the last 1 week, and is up 10.27% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 5.96% and the 50-Day Moving Average is 0.76%.The 200 Day SMA reached 20.66% Endologix Inc. is up 3.45% in the last 3-month period. Year-to-Date the stock performance stands at 30.1%.
Endologix (ELGX) : The highest short term price target forecast on Endologix (ELGX) is $16 and the lowest target price is $12. A total of 8 equity analysts are currently covering the company. The average price of all the analysts is $14.81 with a standard deviation of $1.51.
For the current week, the company shares have a recommendation consensus of Buy. Endologix (NASDAQ:ELGX): The stock opened at $12.71 and touched an intraday high of $12.945 on Friday. During the day, the stock corrected to an intraday low of $12.52, however, the bulls stepped in and pushed the price higher to close in the green at $12.88 with a gain of 1.58% for the day. The total traded volume for the day was 966,947. The stock had closed at $12.88 in the previous trading session.
Endologix, Inc. is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Companys products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms: traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens. The EVAR products include the Endologix AFX Endovascular AAA System (AFX) and the Endologix Powerlink with Intuitrak Delivery System (Intuitrak). The Companys EVAS product is based on the Nellix platform to seal the aneurysm and provide blood flow to the legs through two blood lumens.